White Pine Capital LLC acquired a new stake in Labcorp Holdings Inc. (NYSE:LH – Free Report) during the 3rd quarter, Holdings Channel.com reports. The fund acquired 1,568 shares of the medical research company’s stock, valued at approximately $483,000.
A number of other hedge funds also recently modified their holdings of the stock. Allied Private Wealth LLC bought a new stake in shares of Labcorp during the 2nd quarter worth about $33,000. William Mack & Associates Inc. acquired a new position in Labcorp in the 3rd quarter valued at about $42,000. Pathway Financial Advisers LLC acquired a new position in Labcorp in the 3rd quarter valued at about $43,000. Jones Financial Companies Lllp acquired a new position in Labcorp in the 2nd quarter valued at about $58,000. Finally, Ancora Advisors LLC bought a new position in Labcorp in the 2nd quarter valued at about $67,000. Institutional investors and hedge funds own 95.94% of the company’s stock.
Labcorp Stock Up 0.5%
LH opened at $372.38 on Tuesday. Labcorp Holdings Inc. has a fifty-two week low of $245.00 and a fifty-two week high of $375.10. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.22 and a current ratio of 1.41. The company has a market capitalization of $30.24 billion, a P/E ratio of 30.55, a P/E/G ratio of 2.10 and a beta of 0.86. The stock has a fifty day moving average of $330.51 and a 200-day moving average of $293.10.
Labcorp Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Tuesday, November 24th will be paid a $0.72 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $2.88 annualized dividend and a yield of 0.8%. Labcorp’s payout ratio is 23.63%.
Wall Street Analysts Forecast Growth
LH has been the subject of several research reports. HSBC upgraded shares of Labcorp from a “hold” rating to a “buy” rating and set a $410.00 price objective for the company in a research report on Thursday, November 5th. Deutsche Bank reaffirmed a “hold” rating and issued a $355.00 target price on shares of Labcorp in a research report on Thursday, October 29th. Robert W. Baird upped their target price on Labcorp from $361.00 to $396.00 and gave the company an “outperform” rating in a research report on Thursday, October 29th. JPMorgan Chase & Co. increased their target price on Labcorp from $330.00 to $360.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Finally, Barclays lifted their price target on Labcorp from $330.00 to $380.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $369.08.
View Our Latest Research Report on LH
Insiders Place Their Bets
In other Labcorp news, EVP Bryan T. Vaughn sold 306 shares of the stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $353.70, for a total transaction of $108,232.20. Following the transaction, the executive vice president owned 6,845 shares in the company, valued at $2,421,076.50. This represents a 4.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Brian J. Caveney sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $372.04, for a total transaction of $744,080.00. Following the transaction, the executive vice president directly owned 34,562 shares in the company, valued at $12,858,446.48. This represents a 5.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 3,384 shares of company stock worth $1,241,707 in the last quarter. 0.84% of the stock is currently owned by corporate insiders.
Labcorp Company Profile
Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences company that provides diagnostic testing and services to patients, physicians, hospitals, employers and other health care organizations. Its offerings include routine and specialty laboratory tests, anatomic pathology and genetic testing. The company also supports pharmaceutical and biotechnology companies with laboratory services for drug development and clinical trials, including testing and analysis used in research and clinical studies.
Read More
- Five stocks we like better than Labcorp
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH – Free Report).
Receive News & Ratings for Labcorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Labcorp and related companies with MarketBeat.com's FREE daily email newsletter.
